Your patents are sitting still. The market isn't.

When a company makes a move your patent covers, the outreach is already written.

🔍

Find dormant patents

We index your full granted portfolio, including the patents that have never been licensed and aren’t on anyone’s shortlist.

📡

Match patents to real market moves

We monitor SEC filings, FDA clearances, funding announcements, and product launches, then match them against your patent claims.

📄

A sheet ready to send

Strong matches come with a one page Technology Commercial Sheet and a drafted outreach email. Edit, then send.

📬 Digest delivery

Matches arrive in your inbox.
Only when there's something real.

You don't go looking. The match finds you.

From:Trailhead IP <notifications@trailheadip.com>

Subject:3 new licensing matches in your portfolio

Trailhead IP

Hi Jane,

Your May 12 scout run surfaced 3 new licensing matches in your portfolio.

Why now — 510(k) clearance starts a 6-month commercialization window and they have no internal delivery IP.

CardioMed Therapeutics filed FDA 510(k) K261823 on Apr 28 2026 for a sustained-release peptide formulation, with a planned commercial launch in Q3.

US10,123,456 B2

Open match →

Why now — Their funding announcement explicitly references calibration techniques that map to claims 1–4 of this patent.

Velociflux Inc. announced a $42M Series B led by Andreessen Horowitz on May 2 2026, naming high-precision flow measurement in pharma manufacturing as their lead vertical.

US11,402,889 B1

Open match →

See all scout runs →

Trailhead IP — every venture starts somewhere.

One page. Sixty seconds to a yes or no.

FIG. 1

Technology Commercial Sheet · For CardioMed Therapeutics

Sustained-release peptide delivery for controlled-release therapeutics

US10,123,456 B2 · A61K · granted Mar 14 2022
Inventors: M. Chen, S. Patel

Your newly cleared 510(k) needs a controlled-release delivery mechanism. We already own the IP that covers it.

Why this fits you now

Your 510(k) clearance opens a 6-month commercialization window. Licensing this patent removes a launch-blocking risk before you ramp manufacturing, and locks in freedom-to-operate ahead of competitor filings in the same chemistry.

At a glance

A biodegradable matrix that delivers peptide therapeutics at a controlled rate over 12–14 weeks from a single subcutaneous dose — the release profile your filing describes.

How it works

A two-phase polymer matrix encapsulates the peptide; controlled hydrolysis regulates the release curve independent of patient pH or activity.

What our patent protects

The two-phase polymer composition and the method of tuning release rate by adjusting phase ratio — both claimed broadly across peptide and small-molecule payloads.

Discussion topics

Exclusive vs. field-of-use license for cardiac indications
Royalty structure for the K261823 product line
Right of first refusal on the chemistry-tuning method claim

Early access

Be one of the first TTOs to scout your portfolio.

We're opening Trailhead IP to TTOs in small batches. Add your email below, and we'll reach out when slots open at your university.